Board summary
Key figures
93,532
Registered population
59.1% aged 18–64
21.3%
Aged 65+
ICB 19.0% · England 17.9%
8.5%
Ethnic minority (non-White)
3.3% Asian · England 9.6%
33.8%
In IMD quintile 1
ICB 31.9% · England 21.0%
~34,815
Core20 residents (est.)
Resident basis; registered basis ~31,442 · see page 3
16,777
Hypertension register
+4.26% in 3 yrs · England +5.60%
1,169
SMI register
13.9% of Liverpool (LAD)'s
2,911
COPD register
Reviews +0.97% in 3 yrs
Forecast to 2030
18,828
Hypertension patients, 2030
+2,051 on today
68.7%
QRISK ≥20% on statins, 2030
+3.17pp over 3 yrs
5.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Wide practice spread in phone contact ease.
GPPS phone access spans 70.5 pp across 16 practices, while overall good experience spans 56.0 pp, which may reflect unverified local triage variation.
Asthma reviews and BP recording trail England.
Asthma reviews reach 63.8% (England 65.7%, leaving about 2,200 unreviewed) and recent BP readings reach 86.0% (England 90.0%), which may reflect recall gaps.
Breast screening and diabetes control outpace England.
Breast screening coverage rose +14.6% (England +8.4%) to 71.4%, while diabetes HbA1c control without frailty rose +13.8% (England +4.4%).
Population, age and ethnicity
Adults aged 65+ represent 21.3% of registered patients, exceeding borough and national levels
SWAGGA PCN serves 93,532 registered patients across its practices. Adults aged 65+ make up 21.3% (19,958 patients), above Liverpool (15.6%), the ICB (19.0%), and England (17.9%). Patients aged 18–64 represent 59.1% and aged 0–17 comprise 19.6%. Census resident estimates indicate 91.5% White ethnicity (Liverpool 84.0%, ICB 93.0%, England 81.1%) and an 8.5% ethnic minority share; registered-patient ethnicity was not captured. Projected list growth is 2.4% to 2030 under an unverified methodology.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Liverpool (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Liverpool LA) | 3,035 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 81.4% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.5% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Liverpool LA) | 1,652 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Liverpool LA) | 27.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation averages 33.8% across the PCN but spans 100 pp between practices
The PCN Core20 share is 33.8%, above England (21.0%) and the ICB (31.9%) but below Liverpool (54.9%), with an average IMD decile of 4.8. Core20 concentration spans 100 pp across practices, from 0.0% at Storrsdale Medical Centre to 100.0% at Netherley Health Centre, while Speke Hc - Dr Thakur holds 5,308 estimated Core20 patients. Weighted practice share is 33.6%. Wide deprivation variation indicates that clinical review priorities and outreach capacity may need tailoring by practice cohort.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
1,169
SMI register
1.24% recorded prevalence
589
Learning disability register
0.63% recorded prevalence
25
Care homes, 1,099 beds
In the PCN catchment
10.3%
Provide unpaid care
Liverpool (LAD), Census 2021
The PCN records 1,169 patients with severe mental illness (1.2%, above England's 1.0%) and 589 with learning disabilities (0.6%, matching England at 0.6%). The catchment includes 25 care homes with 1,099 beds; registered resident numbers were not captured. Separately, Liverpool local authority recorded 35 rough sleepers in an autumn 2025 snapshot and a 10.3% unpaid care rate, ranking 8 of 39 North West local authorities.
Severe mental illness: physical health checks
Recorded SMI prevalence is 1.2% (England 1.0%, Liverpool (LAD) 1.4%). Annual checks reached 84.3% for blood pressure (England 83.4%) and 82.4% for BMI (England 82.1%). Published individual checks show strong delivery, though comprehensive checks are not captured.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
16,777
Hypertension register
+4.26%
Register growth, 3 yrs
Liverpool (LAD) +2.01% · England +5.60%
+4.40pp
BP control, under 80
≤140/90 · +3.58pp aged 80+
+2,051
More patients by 2030
Forecast 18,828 (19.36%)
Hypertension case-finding and control
Recorded hypertension prevalence is 17.8% (16,777 patients), above Liverpool (14.0%), the ICB (16.8%), and England (15.2%). However, recent blood pressure recording reaches 86.0%, trailing Liverpool (87.8%), the ICB (88.3%), and England (90.0%). Blood pressure control to target is 69.4%, below England (70.3%) and Liverpool (69.8%), though above the ICB (69.1%). In patients aged under 80, control to <= 140/90 mmHg is 66.5% (England 67.8%), while for those aged 80 and over, control reaches 81.3% (England 81.2%). Observation periods between the register and list are unconfirmed. Routine blood pressure recording lags national rates despite high recorded prevalence, meaning unmeasured hypertension patients risk delayed treatment optimisation unless recall is prioritised.
Lipids and statins
Patients with QRISK >= 20% on lipid-lowering therapy reach 61.8%, trailing the ICB (63.2%), England (63.6%), and Liverpool (65.6%). Statin therapy for diabetes patients aged 40 and over without CVD is 70.1% (England 73.2%, ICB 72.4%). Fewer at-risk cardiovascular patients receive lipid-lowering therapy than benchmark rates imply, highlighting an opportunity to prioritise statin initiation.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 176,132 | £2.00 | £1.71 | £1.86 | £352,264 |
| Cardiovascular (all), 2025 | 254,180 | £4.65 | £4.37 | £3.33 | £1,181,937 |
For lipid-regulating drugs in 2026, the PCN prescribed 176,132 items at £2.00 per item, above Liverpool (£1.82), England (£1.86), and the ICB (£1.71), spending £24,658 more than at England's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+0.14%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+2.00%
Asthma prevalence, PCN 3-yr % change
Recorded prevalence is above England for COPD at 3.1% (England 1.9%, Liverpool (LAD) 3.0%) with 2,911 patients, and asthma at 7.0% (England 6.6%, Liverpool (LAD) 6.1%) with 6,172 patients. Asthma annual reviews reached 63.8%, below England (65.7%) and Liverpool (LAD) (64.3%), with three-year growth (+0.1% vs England +4.4%) leaving about 2,200 unreviewed patients. Asthma prescribing reached 2,411 items per 1000 aged 5-19 (England 1,488).
Cancer register and children's immunisation
Cancer prevalence is 4.6% with 4,360 registered patients, above England (3.8%) and Liverpool (LAD) (3.3%). In Q1 2025/26, 6-in-1 coverage at 12 months was 89.3% (England 91.0%). At age 5, an 8.2 pp gap separates MMR dose 1 (89.4%) from dose 2 (81.2%, England 82.8%; cohort 207), below the 95.0% target, while 4-in-1 booster coverage was 82.1%.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
At ICB level (not PCN level), across NHS Cheshire and Merseyside ICB in 2022, 55.5% of staged cancers were diagnosed at stage 1 or 2 (72.8% known stage), falling 19.5 pp below the 75.0% national ambition, an ICB gap of about 2,640 cases. From 2013 to 2022, ICB early-stage share rose +2.6 pp from 52.8% to 55.5%. At PCN level, SWAGGA PCN recorded cancer prevalence is 4.6% (4,360 patients; England 3.8%). Cervical screening coverage is 70.3% (England 66.8%), but Garston Family Health Centre recorded 60.5% and Netherley Health Centre recorded 61.7%. Supporting early diagnosis requires addressing these practice screening shortfalls.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At provider and ICB level (not PCN level), for Mersey and West Lancashire Teaching Hospitals NHS Trust, performance on the 62-day referral to treatment standard was 7.0 pp below the 85.0% standard, while NHS Cheshire and Merseyside Integrated Care Board was 8.8 pp below. On the 28-day faster diagnosis standard, the trust was 2.6 pp below the 75.0% standard, while the ICB was 2.2 pp above it. On the 31-day combined standard, the trust fell 0.5 pp below the 96.0% target and the ICB fell 0.3 pp below. These figures describe wider system performance rather than PCN delivery.
| Pathways within standard (%) | Mersey and West Lancashire | Liverpool | North Cheshire and Mersey | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 72.39 | 75.47 | 80.21 | 77.25 | 79.32 |
| 31-day treatment (96%) | 95.46 | 90.51 | 98.17 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 77.96 | 73.26 | 83.67 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Mersey and West Lancashire | Liverpool | North Cheshire and Mersey | England |
|---|---|---|---|---|
| MRI | 14.04 | 6.42 | 0.53 | 21.40 |
| CT | 13.08 | 0.71 | 2.32 | 9.92 |
| Echocardiography | 34.88 | 12.55 | 28.04 | 28.48 |
| Colonoscopy | 18.04 | 33.14 | 15.98 | 30.83 |
| Gastroscopy | 18.17 | 44.99 | 20.24 | 29.02 |
| All 15 DM01 tests | 21.17 | 11.50 | 6.34 | 23.14 |
| Community services activity | Liverpool residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 127,380 | 541,280 |
| Referrals | 15,675 | 97,150 |
| Patients with a contact | 24,970 | 146,240 |
Community services (residents of Liverpool), Jun 2026 (provisional). At local authority level (not PCN level), adults aged 65 and over accounted for 65.4% of community health service contacts (83,300 of 127,380 borough residents' contacts) in Liverpool in provisional figures for June 2026. These activity data describe borough-wide community services rather than PCN-specific delivery.
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Village Medical | 103 | 5.7 | 88.9% | 49.4% | 90.6% |
| Speke Hc - Dr | 96 | 95.9 | 69.3% | 79.7% | 88.2% |
| The Ash Surgery | 114 | 1.9 | 63.8% | 77.6% | 85.8% |
| Grassendale | 105 | 5.2 | 69.8% | 72.8% | 85.5% |
| Hillfoot Health | 110 | 25.2 | 65.4% | 75.4% | 85.3% |
| Mather Avenue | 104 | 18.5 | 69.5% | 69.3% | 84.8% |
| Village | 100 | 48.7 | 57.6% | 66.9% | 84.4% |
| Woolton House | 113 | 6.8 | 39.2% | 76.1% | 82.7% |
| Storrsdale | 106 | 0.0 | 70.9% | 65.6% | 81.6% |
| Gateacre | 96 | 56.6 | 57.8% | 68.4% | 81.5% |
| Margaret Thompson | 105 | 85.0 | 55.3% | 70.7% | 79.7% |
| Fulwood Green | 121 | 0.0 | 72.1% | 66.4% | 79.2% |
| Speke Hc - Dr | 87 | 97.3 | 78.6% | 76.3% | 76.0% |
| Garston Family | 98 | 59.0 | 59.1% | 71.8% | 75.9% |
| Gateacre Brow | 120 | 27.0 | 25.5% | 67.4% | 64.6% |
| Netherley | 89 | 100.0 | 18.4% | 58.5% | 34.7% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eight measures trail England, led by heart failure review growth lagging 6.22 points
Eight measures trail England over three years, led by heart failure reviews gaining +2.5% (England +8.7%, 6.22 points behind) and asthma reviews gaining +0.1% (England +4.4%, 4.3 points behind). COPD reviews also lagged at +1.0% (England +2.8%). Conversely, three-year relative growth outpaced England in non-frail diabetes HbA1c control at +13.8% (England +4.4%) and breast screening at +14.6% (England +8.4%), while mental health blood pressure checks rose +9.1 pp (England +4.4 pp). Slower chronic disease review growth may reflect recall backlog, which clinical audit would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Asthma reviews
COPD register
COPD reviews
Stroke register
Diabetes HbA1c control
Breast screening (53-70)
BP check (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Liverpool (LAD) | Asset | PCN | Liverpool (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 25 (1,099 beds) | n/a | Schools (catchment) | 122 | n/a |
| Children's centres | 6 | 26 | Places of worship | 40 | 240 |
| Libraries | 4 | 17 | Homelessness support (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 22 | 91 | Primary academies | 6 | 20 |
| Special schools | 2 | 8 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review recall
Asthma review coverage is 63.8% (Liverpool (LAD) 64.3%, ICB 62.3%, England 65.7%) with 3-year growth of +0.1% (England +4.4%), leaving about 2,200 of 6,172 register patients unreviewed. For discussion, practices could run a single-template asthma recall prioritising high-deprivation lists and combining inhaler checks with flexible review slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Hypertension and lipid therapy recall
Across 16,777 hypertension patients (17.8% vs England 15.2%), recent BP recording is 86.0% (Liverpool (LAD) 87.8%, ICB 88.3%, England 90.0%) and QRISK >= 20% lipid therapy is 61.8% (England 63.6%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Age-five pre-school immunisation recall
In Q1 2025/26 (cohort 207), age-5 4-in-1 coverage is 82.1% (ICB 82.9%, England 80.9%), 12.9 pp below the 95.0% target, and MMR2 is 81.2% (8.2 pp below MMR1 at 89.4%). For discussion, practices could audit children approaching age five for missing MMR2 and 4-in-1 boosters and offer combined catch-up slots. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult capacity planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 clinical review outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health checks (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall and monitoring (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school immunisation call-recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Screening uptake audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured asthma review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Hypertension and lipid therapy recall (p12) | Registered population · Hypertension register · Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Age-five pre-school immunisation recall (p12) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 · MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
